Form 4: MDXG CFO Doug Rice Granted Significant Equity Awards

MiMedx Group's CFO, Doug Rice, received significant equity grants including restricted stock and stock options, aligning his incentives with long-term company performance.

Summary

• Doug Rice, Chief Financial Officer of MiMedx Group, Inc. (MDXG), was granted 74,163 shares of common stock as restricted stock on March 4, 2026.
• The restricted stock vests fully on the third anniversary of the grant date, contingent on continued employment.
• Mr. Rice also received a grant of 62,068 stock options with an exercise price of $5.10 per share on March 4, 2026.
• These stock options will vest 25% on each anniversary of the grant date, subject to continued employment.
• Following these transactions, Mr. Rice beneficially owns 265,678 shares of common stock and 263,309 derivative securities (stock options).
• The reported beneficial ownership of common stock includes 3,491 shares acquired on January 30, 2026, through the MiMedx Group, Inc. Employee Stock Purchase Plan.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as it strengthens the alignment between executive compensation and long-term shareholder interests, indicating management's commitment to the company's future.

Positives

• The significant equity grants to the Chief Financial Officer align management's financial interests directly with long-term shareholder value creation.
• The vesting schedules for both restricted stock (three years) and stock options (four years, 25% annually) incentivize sustained performance and retention of key executive talent.

Future Outlook

The equity grants are structured with multi-year vesting schedules, indicating an expectation of continued employment for the Chief Financial Officer and a long-term focus on company performance and shareholder value creation.

Industry Context

StockSavvy.ai notes that significant equity grants to key executives like the CFO are a standard practice in the biotechnology and medical device industries. These grants are designed to align executive incentives with long-term company performance and shareholder returns, fostering stability and strategic execution.

Comparison to Industry Standards

• The structure of these equity awards, including multi-year vesting for both restricted stock and stock options, is consistent with typical executive compensation packages observed across the healthcare and biotech sectors.
• The grant size for a CFO in a company of MiMedx Group's market capitalization appears to be within the expected range for retaining and incentivizing senior leadership, comparable to similar grants at companies like Organogenesis Holdings Inc. (ORGO) or Integra LifeSciences Holdings Corporation (IART) for their respective executive teams.

Stakeholder Impact

• Shareholders: The equity grants align the CFO's financial incentives with the company's long-term performance, potentially benefiting shareholders through increased focus on value creation.
• Employees: The grants may signal stability in executive leadership, which can positively impact employee morale and confidence in the company's direction.

Next Steps

• The restricted stock will vest fully on March 4, 2029, subject to continued employment.
• The stock options will vest 25% annually, starting March 4, 2027, and continuing for three subsequent anniversaries, subject to continued employment.

Key Dates

Keywords

MDXG, MiMedx Group, Doug Rice, CFO, equity grant, restricted stock, stock options, insider transaction, Form 4, executive compensation